Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Reaffirmed as Buy by Truist Financial

Madrigal Pharmaceuticals (NASDAQ:MDGL)‘s stock had its “buy” rating reiterated by analysts at Truist Financial in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $743.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $709.00. Truist Financial‘s target price points to a potential upside of 94.01% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 31st. The Goldman Sachs Group started coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target for the company. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Barclays reduced their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $703.80.

Madrigal Pharmaceuticals Stock Performance

Madrigal Pharmaceuticals stock traded down $13.35 during trading on Wednesday, reaching $382.98. The company had a trading volume of 1,084,207 shares, compared to its average volume of 340,282. Madrigal Pharmaceuticals has a 52 week low of $353.54 and a 52 week high of $615.00. The firm’s 50-day simple moving average is $494.64 and its 200 day simple moving average is $498.92. The firm has a market capitalization of $8.85 billion, a price-to-earnings ratio of -29.34 and a beta of -0.98. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%. The company had revenue of $431.27 million for the quarter, compared to the consensus estimate of $404.17 million. During the same period in the previous year, the business earned ($5.08) earnings per share. Sell-side analysts forecast that Madrigal Pharmaceuticals will post -7.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 664 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, August 17th. The shares were sold at an average price of $514.97, for a total value of $341,940.08. Following the sale, the general counsel directly owned 11,474 shares in the company, valued at approximately $5,908,765.78. The trade was a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 6,362 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the transaction, the chief executive officer owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 12,247 shares of company stock worth $6,581,182 in the last three months. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Persistent Asset Partners Ltd purchased a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth $29,000. Global Retirement Partners LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $34,000. Provenance Wealth Advisors LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at about $69,000. Root Financial Partners LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at about $82,000. Finally, GAMMA Investing LLC raised its position in shares of Madrigal Pharmaceuticals by 35.4% during the 2nd quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 45 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Third-quarter EPS was $1.83, well ahead of analysts’ expected loss of $1.09, while revenue of $431.27 million topped estimates of $404.17 million. Rezdiffra sales reportedly surpassed $1 billion, with sales up 50%. Madrigal third-quarter 2026 results
• Positive Sentiment: Citigroup raised its price target to $760 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Citigroup price-target update
• Neutral Sentiment: Madrigal expects a MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a study of more than 2,000 patients. These programs may provide future catalysts, but the timing is relatively distant. Clinical-trial update
• Negative Sentiment: Despite the earnings beat, coverage pointed to near-term profitability concerns as a factor behind the stock’s weakness. Separately, Kaplan Fox announced an investigation into potential securities-law violations. The announcement is an investigation notice, not a finding of wrongdoing. Report on profitability concerns Kaplan Fox investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.